These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23217386)

  • 1. MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation.
    Liu SY; Liang Y; Lin TX; Su F; Liang WW; Uwe H; Li Y
    Chin Med J (Engl); 2012 Dec; 125(23):4197-201. PubMed ID: 23217386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt.
    Liu S; Li Y; Lin T; Fan X; Liang Y; Heemann U
    Diabetes Res Clin Pract; 2011 Feb; 91(2):177-82. PubMed ID: 21129803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression.
    Huth HW; Albarnaz JD; Torres AA; Bonjardim CA; Ropert C
    Cell Signal; 2016 Sep; 28(9):1283-1291. PubMed ID: 27181679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
    Hong SK; Wu PK; Karkhanis M; Park JI
    Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of MEK inhibitors on rat neural stem cell differentiation: Repressive roles of MEK2 in neurogenesis and induction of astrocytogenesis by PD98059.
    Lee HR; Lee J; Kim HJ
    Pharmacol Res; 2019 Nov; 149():104466. PubMed ID: 31562895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK1 and MEK2 isoforms regulate distinct functions in pancreatic cancer cells.
    Zhou L; Tan X; Kamohara H; Wang W; Wang B; Liu J; Egami H; Baba H; Dai X
    Oncol Rep; 2010 Jul; 24(1):251-5. PubMed ID: 20514469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
    Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
    Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
    Zhang YX; Kong CZ
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.
    Voisin L; Julien C; Duhamel S; Gopalbhai K; Claveau I; Saba-El-Leil MK; Rodrigue-Gervais IG; Gaboury L; Lamarre D; Basik M; Meloche S
    BMC Cancer; 2008 Nov; 8():337. PubMed ID: 19014680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Leydig cell MEK/ERK pathway is critical for maintaining a functional population of adult Leydig cells and for fertility.
    Yamashita S; Tai P; Charron J; Ko C; Ascoli M
    Mol Endocrinol; 2011 Jul; 25(7):1211-22. PubMed ID: 21527500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Activation of HIF-1 by bFGF in breast cancer: role of PI-3K and MEK1/ERK pathways].
    Shi YH; Wang YX; You JF; Heng WJ; Zhong HH; Fang WG
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1899-903. PubMed ID: 15631803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
    Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
    Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective transcriptional down-regulation of human rhinovirus-induced production of CXCL10 from airway epithelial cells via the MEK1 pathway.
    Zaheer RS; Koetzler R; Holden NS; Wiehler S; Proud D
    J Immunol; 2009 Apr; 182(8):4854-64. PubMed ID: 19342664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK1/2 overactivation can promote growth arrest by mediating ERK1/2-dependent phosphorylation of p70S6K.
    Guégan JP; Ezan F; Gailhouste L; Langouët S; Baffet G
    J Cell Physiol; 2014 Jul; 229(7):903-15. PubMed ID: 24501087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
    Lee SY; Shin SJ; Kim HS
    Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression.
    Chen T; Yang M; Yu Z; Tang S; Wang C; Zhu X; Guo J; Li N; Zhang W; Hou J; Liu H; Han C; Liu Q; Gu Y; Qian C; Wan T; Cui L; Zhu M; Zheng W; Cao X
    Cancer Cell; 2014 May; 25(5):682-96. PubMed ID: 24746703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards the development of chromone-based MEK1/2 modulators.
    Redwan IN; Dyrager C; Solano C; Fernández de Trocóniz G; Voisin L; Bliman D; Meloche S; Grøtli M
    Eur J Med Chem; 2014 Oct; 85():127-38. PubMed ID: 25078316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
    Senawong T; Phuchareon J; Ohara O; McCormick F; Rauen KA; Tetsu O
    Hum Mol Genet; 2008 Feb; 17(3):419-30. PubMed ID: 17981815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
    Caunt CJ; Sale MJ; Smith PD; Cook SJ
    Nat Rev Cancer; 2015 Oct; 15(10):577-92. PubMed ID: 26399658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing MEK1 activation influences the responses of human osteosarcoma cells to bone morphogenetic proteins 2 and 9.
    Park H; Drevelle O; Daviau A; Senta H; Bergeron E; Faucheux N
    Anticancer Drugs; 2013 Mar; 24(3):278-90. PubMed ID: 23262982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.